Company profile: TriLink BioTechnologies
1.1 - Company Overview
Company description
- Provider of custom oligonucleotides, modified nucleotides, long RNA and mRNA for the diagnostic, therapeutic and OEM markets, offering mRNA synthesis services and GMP mRNA manufacturing, CleanCap capping solutions, custom NTPs, specialty oligo synthesis, and in-house analytical method development and testing; also supplies CleanAmp PCR products and phosphoramidites.
Products and services
- GMP mRNA manufacturing: GMP-compliant, engineers scale-up mRNA production, supported by extensive in-house analytical services for comprehensive mRNA characterization, ensuring process quality and consistency
- CleanCap® capping solutions: High-efficiency one-pot system for mRNA capping, achieving over 95% efficiency in generating Cap1 structure
- MRNA synthesis services: Proprietary in vitro transcription method optimized to decrease dsRNA, with scalable production from milligram to multi-gram quantities
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TriLink BioTechnologies
Bluebird Bio
HQ: United States
Website
- Description: Provider of gene therapies for severe genetic and rare diseases, developing gene addition treatments that modify patient cells to address underlying genetic causes using lentiviral vectors. Products include LentiGlobin for sickle cell disease, Lenti-D for cerebral adrenoleukodystrophy, and Zynteglo for beta-thalassemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluebird Bio company profile →
ReadCoor
HQ: United States
Website
- Description: Provider of the first true spatial multi-omic platform (RC2) that simultaneously detects and reads sequences, serving a global audience of researchers, clinicians, pharma and diagnostics companies to expand understanding of human biology and facilitate the creation of new therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ReadCoor company profile →
Amyris
HQ: United States
Website
- Description: Provider of biotech chemical products made via advanced sugarcane-derived fermentation. Portfolio includes Neossance Squalane for cosmetics and skincare moisturization and barrier repair; Artemisinic Acid used in antimalarial treatments; Biosilica from sugarcane ashes for cosmetics; Neossance Hemisqualane as a plant-based silicone alternative; Biofene renewable specialty chemical building block; RealSweet Reb M zero-calorie sweetener.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amyris company profile →
BioFluidica
HQ: United States
Website
- Description: Provider of a biotechnology diagnostic platform and automated liquid biopsy microfluidic system to isolate and enrich rare biomarkers—circulating tumor cells, exosomes, and trophoblasts—from body fluids; offers exosome and CTC isolation for research and cbNIPT, plus the B³ Blood Collection Tube for room-temperature whole blood shipping with buffer to inhibit micro-clotting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioFluidica company profile →
Krystal Biotech
HQ: United States
Website
- Description: Provider of gene therapies, including FDA-approved VYJUVEK for delivering missing or defective genes to the skin; with focus on Autosomal Recessive Congenital Ichthyosis, Netherton Syndrome, Cystic Fibrosis, and Alpha-1 Antitrypsin Deficiency; and oncology development using a modified HSV-1 vector to deliver IL-12 and IL-2 to the tumor microenvironment for immune-mediated tumor clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Krystal Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TriLink BioTechnologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TriLink BioTechnologies
2.2 - Growth funds investing in similar companies to TriLink BioTechnologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TriLink BioTechnologies
4.2 - Public trading comparable groups for TriLink BioTechnologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →